1. Home
  2. TKLF vs CALC Comparison

TKLF vs CALC Comparison

Compare TKLF & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yoshitsu Co. Ltd

TKLF

Yoshitsu Co. Ltd

N/A

Current Price

$1.98

Market Cap

8.2M

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

N/A

Current Price

$0.89

Market Cap

9.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TKLF
CALC
Founded
2006
2011
Country
Japan
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
9.7M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
TKLF
CALC
Price
$1.98
$0.89
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
106.3K
297.3K
Earning Date
12-19-2025
05-13-2026
Dividend Yield
10.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.82
$3.05
Revenue Growth
N/A
N/A
52 Week Low
$1.76
$0.46
52 Week High
$4.32
$7.20

Technical Indicators

Market Signals
Indicator
TKLF
CALC
Relative Strength Index (RSI) 40.41 61.03
Support Level N/A $0.52
Resistance Level $2.41 $0.93
Average True Range (ATR) 0.24 0.11
MACD 0.00 0.02
Stochastic Oscillator 14.92 59.67

Price Performance

Historical Comparison
TKLF
CALC

About TKLF Yoshitsu Co. Ltd

Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: